Compugen Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

CompugenDer Gewinn des Unternehmens wird voraussichtlich um 22.2% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 10.8% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich zurückgehen.

Wichtige Informationen

-22.2%

Wachstumsrate der Gewinne

-2.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	10.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	14 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

May 22

Recent updates

Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

Aug 22

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

May 22

Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

May 01

Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Apr 05

Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Mar 08

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 04

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Sep 21

Compugen appoints Alberto Sessa as CFO

Sep 12

Compugen gets Japanese patent for COM701, anti-PVRIG antibodies

Aug 24

Compugen Q2 2022 Earnings Preview

Aug 03

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Jun 23

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Mar 02

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 04

Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Aug 27

Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Jun 28

Compugen gains on takeover speculation after iTeos Therapeutics deal

Jun 14

Compugen reports updated COM701 data from Phase 1 study at ASCO21

Jun 08

Compugen's COM902 demonstrates potential benefit in cancer

Apr 27

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 15

Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?

Feb 08

A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)

Jan 04

Compugen earns $2M milestone under antibody development deal with AstraZeneca

Dec 23

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 30

Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

Compugen: Speculative Play For Immuno-Oncology Exposure

Nov 07

Compugen Q3 Earnings Preview

Nov 04

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:CGEN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	39	-15	15	-28	2
12/31/2025	43	-2	2	-14	2
12/31/2024	43	-2	66	43	2
6/30/2024	43	-10	22	22	N/A
3/31/2024	36	-17	N/A	N/A	N/A
12/31/2023	33	-19	-36	-36	N/A
9/30/2023	8	-32	N/A	N/A	N/A
6/30/2023	8	-33	-32	-32	N/A
3/31/2023	8	-33	N/A	N/A	N/A
12/31/2022	8	-34	-35	-34	N/A
9/30/2022	N/A	-39	N/A	N/A	N/A
6/30/2022	6	-34	-30	-30	N/A
3/31/2022	6	-34	N/A	N/A	N/A
12/31/2021	6	-34	-23	-23	N/A
9/30/2021	8	-34	N/A	N/A	N/A
6/30/2021	2	-36	-31	-30	N/A
3/31/2021	2	-32	N/A	N/A	N/A
12/31/2020	2	-30	-28	-28	N/A
9/30/2020	N/A	-28	N/A	N/A	N/A
6/30/2020	N/A	-26	-23	-23	N/A
3/31/2020	N/A	-26	N/A	N/A	N/A
12/31/2019	N/A	-27	-28	-28	N/A
9/30/2019	N/A	-30	N/A	N/A	N/A
6/30/2019	8	-27	-22	-22	N/A
3/31/2019	8	-31	N/A	N/A	N/A
12/31/2018	18	-23	-13	-13	N/A
9/30/2018	18	-23	N/A	N/A	N/A
6/30/2018	10	-29	-24	-23	N/A
3/31/2018	10	-28	N/A	N/A	N/A
12/31/2017	N/A	-37	N/A	-31	N/A
9/30/2017	0	-36	N/A	N/A	N/A
6/30/2017	0	-34	N/A	-27	N/A
3/31/2017	1	-32	N/A	N/A	N/A
12/31/2016	1	-32	N/A	-20	N/A
9/30/2016	9	-23	N/A	N/A	N/A
6/30/2016	9	-22	N/A	-20	N/A
3/31/2016	9	-23	N/A	N/A	N/A
12/31/2015	9	-20	N/A	-26	N/A
9/30/2015	8	-21	N/A	N/A	N/A
6/30/2015	9	-20	N/A	-17	N/A
3/31/2015	11	-15	N/A	N/A	N/A
12/31/2014	12	-11	N/A	-11	N/A
9/30/2014	8	-13	N/A	N/A	N/A
6/30/2014	7	-12	N/A	-7	N/A
3/31/2014	6	-13	N/A	N/A	N/A
12/31/2013	4	-14	N/A	-6	N/A
9/30/2013	2	-17	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CGEN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CGEN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CGEN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CGENDie Einnahmen des Unternehmens (10.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.8% pro Jahr).

Hohe Wachstumseinnahmen: CGENDie Einnahmen des Unternehmens (10.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CGEN in 3 Jahren voraussichtlich hoch sein wird

Compugen Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast to breakeven in 2025

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

Consensus revenue estimates increase by 41%, EPS downgraded

Consensus revenue estimates fall by 45%

Consensus EPS estimates upgraded to US$0.31 loss

Price target decreased by 7.0% to US$5.50

Recent updates

Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

New minor risk - Profitability

New major risk - Revenue and earnings growth

Forecast to breakeven in 2025

Compugen Ltd., Annual General Meeting, Sep 12, 2024

Compugen Ltd. Announces FDA Clearance of IND for Com503 for the Treatment of Solid Tumors

Compugen Ltd. to Report Q2, 2024 Results on Aug 06, 2024

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

Compugen Ltd. Announces CFO Changes, Effective August 15, 2024

Compugen Ltd. to Report Q1, 2024 Results on May 20, 2024

Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

New minor risk - Shareholder dilution

Consensus revenue estimates increase by 41%, EPS downgraded

Now 23% undervalued

New major risk - Revenue and earnings growth

Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Compugen Ltd. to Report Q4, 2023 Results on Mar 05, 2024

Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Compugen Ltd. Announces Executive Changes

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 45%

Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification

Compugen Ltd. Announces to Present New Data At Sitc 2023 Suggesting Leading Edge of Anti-Il18 Binding Protein Antibody, Com503, in Treating Cancer

Compugen Ltd. to Report Q3, 2023 Results on Nov 07, 2023

Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Insufficient new directors

New major risk - Revenue and earnings growth

Consensus EPS estimates upgraded to US$0.31 loss

Compugen Ltd., Annual General Meeting, Sep 20, 2023

Compugen Ltd. to Report Q2, 2023 Results on Aug 07, 2023

Price target decreased by 7.0% to US$5.50

Compugen Ltd. Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-Of-Concept Study

Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Price target increased by 15% to US$6.80

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Compugen Ltd. to Report Q4, 2022 Results on Feb 27, 2023

Compugen Ltd.'s COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer

Price target decreased to US$6.29

Compugen Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients

Compugen Announces Receipt of Nasdaq Delisting Notice

Compugen Ltd. to Report Q3, 2022 Results on Nov 14, 2022

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen Ltd. Announces Appointment of Alberto Sessa as Chief Financial Officer

Compugen appoints Alberto Sessa as CFO

Compugen gets Japanese patent for COM701, anti-PVRIG antibodies

Compugen Ltd. Announces Resignation of Ari Krashin as Chief Operating Officer in August 2022

Compugen Q2 2022 Earnings Preview

Compugen Ltd. to Report Q2, 2022 Results on Aug 04, 2022

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen Announces CFO Departure

Compugen Ltd. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$14.00

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen Ltd. Announces Board Changes

Compugen Ltd. to Report Q4, 2021 Results on Feb 24, 2022

Price target decreased to US$18.57

Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use with anti-PD-1 and anti-TIGIT Antibodies

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development

High number of new directors

Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207

Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies

Senior VP & Chief Medical Officer notifies of intention to sell stock

Compugen Doses First Patient in COM701/Opdivo® (nivolumab) Phase 1b Cohort Expansion Study

Compugen Ltd. Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axis

Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth